Cargando…
A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
While traditional cytotoxic agents play a limited role in advanced dermatofibrosarcoma protuberans (DFSP), the treatment of sunitinib for patients with advanced DFSP after imatinib failure is not well defined. The objective of this case report was to analyze the relationship between molecular mechan...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937482/ https://www.ncbi.nlm.nih.gov/pubmed/29760553 http://dx.doi.org/10.2147/OTT.S150235 |
_version_ | 1783320632978571264 |
---|---|
author | Xiao, Wei Que, Yi Peng, Ruiqing Ding, Ya Zhao, Jingjing Wen, Xizhi Weng, Desheng Zhang, Xiaoshi Guan, Yuanxiang Zhang, Xing |
author_facet | Xiao, Wei Que, Yi Peng, Ruiqing Ding, Ya Zhao, Jingjing Wen, Xizhi Weng, Desheng Zhang, Xiaoshi Guan, Yuanxiang Zhang, Xing |
author_sort | Xiao, Wei |
collection | PubMed |
description | While traditional cytotoxic agents play a limited role in advanced dermatofibrosarcoma protuberans (DFSP), the treatment of sunitinib for patients with advanced DFSP after imatinib failure is not well defined. The objective of this case report was to analyze the relationship between molecular mechanisms and clinical outcomes of sunitinib treatment in patients with advanced DFSP after imatinib failure. In this case report, a 37-year-old man suffered from advanced DFSP progression after surgical operation, microwave ablation, and chemotherapy. The immunohistochemistry in this patient revealed abundant expression of platelet-derived growth factor receptor-beta on tumor cells, which is one of the drug targets of sunitinib. The nucleotide sequence analysis revealed COL1A1-PDGFB fusion transcripts in this patient. Thus, we treated the patient with sunitinib, a multi-targeted tyrosine kinase inhibitor, after imatinib failure. After treatment with sunitinib, the patient exhibited a partial response and 9 months’ progression-free survival without significant adverse drug effects. In our case, the patient with advanced DFSP experienced a favorable outcome in 9-months’ progression-free survival and a significant improvement of quality of life without serious side effects after sunitinib treatment. Therefore, sunitinib could serve as another treatment option for patients with advanced DFSP. |
format | Online Article Text |
id | pubmed-5937482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-59374822018-05-14 A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure Xiao, Wei Que, Yi Peng, Ruiqing Ding, Ya Zhao, Jingjing Wen, Xizhi Weng, Desheng Zhang, Xiaoshi Guan, Yuanxiang Zhang, Xing Onco Targets Ther Case Report While traditional cytotoxic agents play a limited role in advanced dermatofibrosarcoma protuberans (DFSP), the treatment of sunitinib for patients with advanced DFSP after imatinib failure is not well defined. The objective of this case report was to analyze the relationship between molecular mechanisms and clinical outcomes of sunitinib treatment in patients with advanced DFSP after imatinib failure. In this case report, a 37-year-old man suffered from advanced DFSP progression after surgical operation, microwave ablation, and chemotherapy. The immunohistochemistry in this patient revealed abundant expression of platelet-derived growth factor receptor-beta on tumor cells, which is one of the drug targets of sunitinib. The nucleotide sequence analysis revealed COL1A1-PDGFB fusion transcripts in this patient. Thus, we treated the patient with sunitinib, a multi-targeted tyrosine kinase inhibitor, after imatinib failure. After treatment with sunitinib, the patient exhibited a partial response and 9 months’ progression-free survival without significant adverse drug effects. In our case, the patient with advanced DFSP experienced a favorable outcome in 9-months’ progression-free survival and a significant improvement of quality of life without serious side effects after sunitinib treatment. Therefore, sunitinib could serve as another treatment option for patients with advanced DFSP. Dove Medical Press 2018-05-01 /pmc/articles/PMC5937482/ /pubmed/29760553 http://dx.doi.org/10.2147/OTT.S150235 Text en © 2018 Xiao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Xiao, Wei Que, Yi Peng, Ruiqing Ding, Ya Zhao, Jingjing Wen, Xizhi Weng, Desheng Zhang, Xiaoshi Guan, Yuanxiang Zhang, Xing A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure |
title | A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure |
title_full | A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure |
title_fullStr | A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure |
title_full_unstemmed | A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure |
title_short | A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure |
title_sort | favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937482/ https://www.ncbi.nlm.nih.gov/pubmed/29760553 http://dx.doi.org/10.2147/OTT.S150235 |
work_keys_str_mv | AT xiaowei afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT queyi afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT pengruiqing afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT dingya afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT zhaojingjing afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT wenxizhi afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT wengdesheng afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT zhangxiaoshi afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT guanyuanxiang afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT zhangxing afavorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT xiaowei favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT queyi favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT pengruiqing favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT dingya favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT zhaojingjing favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT wenxizhi favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT wengdesheng favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT zhangxiaoshi favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT guanyuanxiang favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure AT zhangxing favorableoutcomeofadvanceddermatofibrosarcomaprotuberansundertreatmentwithsunitinibafterimatinibfailure |